Company Filing History:
5 out of 157 
3 out of 893 
2 out of 4 Years Active: 1998-1999
Title: Gerald M McMahon: Innovator in Tyrosine Kinase Modulation
Introduction
Gerald M McMahon is a notable inventor based in San Francisco, CA (US). He has made significant contributions to the field of organic molecules, particularly in the modulation of tyrosine kinase signal transduction. With a total of 5 patents, his work has implications for various medical disorders.
Latest Patents
One of his latest patents involves substituted phenylacrylonitrile compounds and compositions that modulate KDR/FLK-1 receptor signal transduction. This invention aims to regulate vasculogenesis and angiogenesis, which are critical processes in the development of blood vessels. The research highlights the association of KDR/FLK-1 tyrosine kinase receptor expression with endothelial cells and identifies vascular endothelial growth factor (VEGF) as a high-affinity ligand of FLK-1. The findings suggest a significant role for KDR/FLK-1 in the signaling system during these processes. Additionally, the invention describes the engineering of host cells that express FLK-1, which can be used to evaluate and screen for drugs and analogs of VEGF that modulate FLK-1 activity. The disclosed compounds have potential applications in treating disorders such as cancer, diabetes, hemangioma, and Kaposi's sarcoma.
Career Highlights
Throughout his career, Gerald has worked with prominent companies, including Sugen Incorporated and Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. His innovative work has positioned him as a key figure in the field of biomedical research.
Collaborations
Gerald has collaborated with notable individuals such as Harald App and Peng Cho Tang, contributing to the advancement of research in his area of expertise.
Conclusion
Gerald M McMahon's contributions to the field of organic molecules and tyrosine kinase modulation have significant implications for medical science. His innovative patents and collaborations reflect his commitment to advancing research and developing treatments for critical health issues.